April 27, 2022
Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.
April 27, 2022
The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.
April 26, 2022
Following respective improvements in odds of good and poor outcomes, investigators concluded that the addition of mechanical thrombectomy should be considered over best medical management practices alone.
April 26, 2022
The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]
April 25, 2022
After readjusting baseline to month 12, more patients with relapsing multiple sclerosis on continuous ozanimod achieved NEDA-3 and NEDA-4 status than those on interferon ß-1a.
April 25, 2022
Despite a low percentage of patients missing work time due to their condition, a higher percentage reported impairment while working, overall work impairment, and activity impairment.
April 24, 2022
Jacqueline A. French, MD, discussed the factors that influence the challenges in treatment selection in epilepsy, and how patient conversations and comprehension of heterogeneity can help in the treatment selection process.
April 24, 2022
The professor of neurology at the University of Basel discussed a recent study presented at AAN 2022 on whether levels of polyunsaturated fatty acids are associated with MS disease activity or progression. [WATCH TIME: 4 minutes]
April 24, 2022
Patients treated with ofatumumab (Kesimpta; Novartis) demonstrated significant decreases in absolute and percent CD19 counts at day 5 of treatment, which persisted through the 90-day period.
April 22, 2022
The neurologist and assistant professor at the University of Toronto provided insight on the differences between outcome measures for Alzheimer disease and how they factored into a new item-level analysis of aducanumab (Aduhelm; Biogen). [WATCH TIME: 3 minutes]
The Success of the Jefferson Mobile Stroke Unit: Alvin Wang, DO, BC-EMS
Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS
Diazepam Nasal Spray Significantly Extends Time Between Seizure Clusters
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc